Stock ARIAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Ariad Pharmaceuticals, Inc.

Equities

US04033A1007

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Ariad Pharmaceuticals, Inc.
2017 Takeda Pharmaceutical : Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal RE
2014 Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ariad Pharmaceuticals : Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
BU
Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion
PU
Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.
PU
Ariad Pharmaceuticals : Acquisition May Not Be in the Best Interests of ARIA Shareholders
PR
Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
BU
Takeda Pharmaceutical : Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion
BU
Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.
BU
Ariad Pharmaceuticals : to Present at the 35th Annual J.P. Morgan Healthcare Conference
BU
Ariad Pharmaceuticals : Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study
BU
Ariad Pharmaceuticals : Announces Data Presentations at American Society of Hematology Meeting
BU
Ariad Pharmaceuticals : Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer
BU
Ariad Pharmaceuticals : to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer
BU
Ariad Pharmaceuticals : Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial
BU
Ariad Pharmaceuticals : Announces Data Presentations at the World Conference on Lung Cancer
BU
Ariad Pharmaceuticals : Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month
BU
Ariad Pharmaceuticals : Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology
BU
Ariad Pharmaceuticals : Reports Third Quarter 2016 Financial Results
BU
Ariad Pharmaceuticals : to Present at the Jefferies 2016 London Healthcare Conference
BU
Ariad Pharmaceuticals : to Webcast Conference Call on Third Quarter 2016 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Ariad Pharmaceuticals, Inc.